← Leaderboards
Melanie N Hurst
Vanderbilt University
$84,841
Attributed
$84,841
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $30.2K · FY2019–21$50K$37.5K$25K$12.5K$0
'19
'20
'21
Funding mix
By agency
NIH$84,841 · 1
By mechanism
F31$84,841 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Antibiotic Resistance”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$25,064,821
- Bruce Blough · Research Triangle Institute$19,880,022
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Terry Roemer · Prokaryotics, Inc.$13,917,276
Research focus
Antibiotic ResistanceAntibioticsAntibiotic TherapyAntimicrobialAttentionBacteriaBacterial ChromosomesBacterial FitnessBacterial ResistanceBase SequenceCationsCellsCodeColistin ResistanceCuesElementsEnsureEnterobacteriaceaeEnvironmentEnzymesEscherichia ColiEventExhibitsAnogenital Region
Grant awards (3)
Elucidating the mechanisms of transient polymyxin resistance in pathogenic E. coli.$24,910
F31 · FY2021 · AI · contact PI
Elucidating the mechanisms of transient polymyxin resistance in pathogenic E. coli.$30,221
F31 · FY2020 · AI · contact PI
Elucidating the mechanisms of transient polymyxin resistance in pathogenic E. coli.$29,710
F31 · FY2019 · AI · contact PI